On November 6, at the 7th China International Import Expo, berry genomics signed a contract with global gene sequencing instrument giant illumina, marking another milestone in their deepened cooperation and joint exploration of new technological areas. This collaboration is about illumina's flagship high-throughput sequencer NovaSeq X Plus project. NovaSeq X Plus can sequence more than 20,000 standard human genomes per year, reducing the cost of sequencing a single person's whole genome to $200, while further enhancing sequencing speed, scale, accuracy, and sustainability. It can support larger-scale, higher-depth sequencing, be compatible with a wider range of research types (from whole genomes to multiomics), and promote the accelerated popularization of gene sequencing technology. (Securities Times)